Designer gene therapy using an Escherichia coli purine nucleoside phosphorylase/prodrug system
about
Insights into Phosphate Cooperativity and Influence of Substrate Modifications on Binding and Catalysis of Hexameric Purine Nucleoside PhosphorylasesNew phosphate binding sites in the crystal structure of Escherichia coli purine nucleoside phosphorylase complexed with phosphate and formycin AProgress and problems with the use of suicide genes for targeted cancer therapyCoupling Protein Side-Chain and Backbone Flexibility Improves the Re-design of Protein-Ligand SpecificityToward a high-throughput screening platform for directed evolution of enzymes that activate genotoxic prodrugs.Enhancement of intratumoral cyclophosphamide pharmacokinetics and antitumor activity in a P450 2B11-based cancer gene therapy model.Development of gene therapy in association with clinically used cytotoxic deoxynucleoside analogues.PRE-CLINICAL AND CLINICAL VALIDATION OF AN ANTI-CANCER MODALITY THAT ABLATES REFRACTORY, LOW GROWTH FRACTION TUMORS.Enzymes to die for: exploiting nucleotide metabolizing enzymes for cancer gene therapy.Effect of expression of adenine phosphoribosyltransferase on the in vivo anti-tumor activity of prodrugs activated by E. coli purine nucleoside phosphorylase.Homooligomerization is needed for stability: a molecular modelling and solution study of Escherichia coli purine nucleoside phosphorylase.Activators of viral gene expression in polarized epithelial monolayers identified by rapid-throughput drug screening.Design and evaluation of 5'-modified nucleoside analogs as prodrugs for an E. coli purine nucleoside phosphorylase mutant.Unique substrate specificity of purine nucleoside phosphorylases from Thermus thermophilus.Crystallographic snapshots of ligand binding to hexameric purine nucleoside phosphorylase and kinetic studies give insight into the mechanism of catalysis
P2860
Q27672664-0CA8E1FE-F325-4FCE-8F7A-021F208A5A5DQ27678965-88E18894-4B27-4586-A296-0B7F0025FE44Q28262370-0C598948-F630-41DD-8A47-7DD8FFED3D01Q28914714-6BEFD496-6194-4971-A8AB-69678D6DF115Q35201410-9F07B90A-9AC5-4DD0-88F8-A0DAFB422CE7Q37037051-ADEEB256-7FF5-4796-9D35-574812140199Q37431500-E8FE782A-4CE8-4232-90D3-38F53B220218Q37563779-9BD5F99F-28B7-4D2B-A51C-0E9E6277F5F7Q37989984-23E22632-77BA-41F5-9ECB-0933B224FBA4Q39577776-60DEE6CD-63C0-43F5-9B60-C70F0D3A1AC1Q40188047-6277FE82-12BE-4632-AFA1-F28BAACF5990Q40347903-93A75355-516B-46ED-B92A-56E7158FE6EDQ40358231-FF91666A-8621-437A-87DC-DE120A83C23AQ43018050-4128D48B-2C19-4E5D-8717-D990791EBD31Q58603689-76A90179-593E-4487-8548-E910E88A419C
P2860
Designer gene therapy using an Escherichia coli purine nucleoside phosphorylase/prodrug system
description
2003 nî lūn-bûn
@nan
2003 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Designer gene therapy using an ...... e phosphorylase/prodrug system
@ast
Designer gene therapy using an ...... e phosphorylase/prodrug system
@en
Designer gene therapy using an ...... e phosphorylase/prodrug system
@nl
type
label
Designer gene therapy using an ...... e phosphorylase/prodrug system
@ast
Designer gene therapy using an ...... e phosphorylase/prodrug system
@en
Designer gene therapy using an ...... e phosphorylase/prodrug system
@nl
prefLabel
Designer gene therapy using an ...... e phosphorylase/prodrug system
@ast
Designer gene therapy using an ...... e phosphorylase/prodrug system
@en
Designer gene therapy using an ...... e phosphorylase/prodrug system
@nl
P2093
P1476
Designer gene therapy using an ...... e phosphorylase/prodrug system
@en
P2093
Abdalla E A Hassan
Dana N Levasseur
David T McPherson
Eric J Sorscher
Eric M Bennett
Jeong S Hong
John A Secrist
Paula W Allan
Ruchi Anand
Tim M Townes
P304
P356
10.1016/J.CHEMBIOL.2003.11.008
P577
2003-12-01T00:00:00Z